Catalyst Event
LigaChem Biosciences Inc (141080) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/18/2026, 12:00:00 AM
Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.
Korean Translation
2026년 3월 18일, 미국암연구학회(AACR)에서 차세대 BCMA 표적 ADC 후보물질 2종에 대한 전임상 결과 발표 예정됨. 주요 학회 발표는 투자자 관심을 유도하므로 중간 수준의 영향이 예상됨.
Related Recent Events
D&D Pharmatech Inc (347850) · Other
Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled
5/31/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 14th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.
3/20/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.
3/18/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.
3/16/2026, 12:00:00 AM
GC Cell Corporation (144510) · Earnings Release
Announced full-year 2025 earnings results, reporting a significant increase in net loss to KRW 272.9 billion from KRW 73.9 billion in the previous year. Basic loss per share widened to KRW 18,158 from KRW 4,918.
3/16/2026, 12:00:00 AM